Truist lowered the firm’s price target on Caribou Biosciences (CRBU) to $21 from $23 but keeps a Buy rating on the shares. The firm’s price target update reflects implementing its revised Lymphoma patient flow model across the CAR-T coverage, Allogene Therapeutics’ (ALLO) ALLO-501A going straight to 1L and shrinking the eligible 2L pool of patients for CB-010, and CB-010 achieving more market share in 2L+ in the absence of ALLO-501A and ADI-001 in that setting, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRBU:
- Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
- Caribou Biosciences provides regulatory update on CB-010 development program
- Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
- Caribou Biosciences multiple myeloma treatment granted FDA orphan status
- Snowflake upgraded, Lucid downgraded: Wall Street’s top analyst calls
